简介：在血流动的Receptor-ligand相互作用是关键的作为煽动性的串联，血小板血栓，以及肿瘤转移开始生物过程。为了调停，房间粘附，交往的受体和ligands必须被抛锚到二个房间或一个房间和一个基础的二apposing表面上，即，二维(2D)绑定，与在到受体的液体阶段的可溶的ligand的绑定不同，三维(3D)有约束力。当众多的工作在免疫系统集中于receptor-ligand相互作用的3D动力学时，2D动力学和它的规定少些被理解，自从没有理论框架和试验性的试金被建立了直到1993。不仅分子的结构统治在血流动的力量也调整的2D绑定动力学，而是shear房间粘附由交往的受体和ligands调停了。这里，我们在2D绑定和规定提供了当前的进步的概述。理论框架，试验性的大小，运动的率和有约束力的亲密关系的相关问题，和力量规定，被讨论。

简介：IncreasedexpressionofFasbyhematopoieticprogenitorsinaplasticanemia(AA)suggeststhatFas/Fasligand(FasL)systemplaysakeyroleintheformationofseverepancytopenia.Tofurtherconfirmtheabovehypothesis,Tcellsfrom8patientswithAAweresystematicallystudiedfortheirFasL'sdistributionpattern,releasingmannerandproapoptoticactivity,comparedwithnormalrestingTcellsandartificiallyactivatedTcellblasts.TheresultsdemonstratedthatAATcellsabnormallyexpressedlowlevelsofmembrane-boundFasLandcontainedhighlevelsofintracellularFasLwhichcouldbetriggeredtoreleasebyhigh-dosephytohemagglutinin(PHA)pulse-stimulation.ThesupernatantsfromthePHA-stimulatedAATcellshadapparentcytotoxicityagainstFasL-sensitiveJurkatcells,whichcouldbesignificantlyinhibitedbymonoclonalantibodyagainstFasLinadose-dependentmanner,ornearlycompletelyabrogatedbyultracentrifugation.TheabovephenomenaalsoappearedonartificiallyactivatedTcellblasts,butthiswasnotthecaseonnormalrestingTcells.TheseresultsindicatethatAATcellisatypeof'preactivated'Tlymphocyte,characterizedbyoverexpressionofFasL,especiallyintracellularFasLwhichcanbestimulatedtoreleaseinbioavtiveexosomesboundform.Takentogether,ourdataprovidefurtheranddirectevidenceforthehypothesisthatTcellsmightmediatethedestructionofhematopieticprogenitorinAAthroughFas/FasLsystem.

简介：Ahallmarkofallformsofneurodegenerativediseasesisimpairmentofneuronalfunctions,andinmanycasesneuronalcelldeath.Althoughtheetiologyofneurodegenerativediseasesmaybedistinct,differentdiseasesdisplayasimilarpathogenesis,forexampleabnormalimmunitywithinthecentralnervoussystem(CNS),activationofmacrophage/microgliaandtheinvolvementofproinflammatorycytokines.Recentstudiesshowthatneuronsinaneurodegenerativestateundergoahighlyregulatedprogrammedcelldeath,alsocalledapoptosis.TNF-relatedapoptosis-inducingligand(TRAIL),amemberoftheTNFfamily,hasbeenshowntobeinvolvedinapoptosisduringmanydiseases.Asonememberofadeathligandfamily,TRAILwasoriginallythoughttotargetonlytumorcellsandwasnotpresentinCNS.However,recentdatashowedthatTRAILwasunregulatedinHIV-1-infectedandimmune-activatedmacrophages,amajordiseaseinducingcellduringHIV-1-associateddementia(HAD).TRAILisalsoinducedonneuronbyβ-amyloidprotein,animportantpathogenforAlzheimer'sdisease.Inthisreview,wesummarizethepossiblecommonaspectsthatTRAILinvolvedthoseneurodegenerativediseases,TRAILinducedapoptosissignalingintheCNScells,andspecificroleofTRAILinindividualdiseases.Cellular&MolecularImmunology.2005;2(2):113-122.

简介：

简介：BandTlymphocyteattenuator(BTLA),identifiedasanimmuneinhibitoryreceptorrecently,playswidespreadrolesonTandBcells.EmergingevidencehasgeneratedplentifulinformationonthemechanismswhichBTLAmediatesnegativeregulationinimmuneresponsesandinvolvesinavarietyofphysiologicalandpathologicalprocesses.TheexplorationofthebiologicalmechanismsandregulationofBTLAwillopenpossibilitiesonnoveltherapeuticstrategiesinimmune-relateddiseases.

简介：ObjectivesToinvestigatetheassociationofsolubleFasligand(sFasL)andsolubleFasreceptor(sFas)withhumanchroniccongestiveheartfailure(CHF).MethodsTheserumlevelofsFasLandsFasin33patientswithCHF(13incardiacfunctionclassⅡ,17inclassⅢ,3inclassⅣ,NYHA)wasassessedwithenzyme-linkedimmunosorbentassay,andwascomparedwiththatof18age-,bloodpressure-matchedpatientswithcardiacfunctionclassⅠ(NYHA).ResultsTherewasnodifferenceinthelevelofsFasLbetweenthetwogroups[CHFgroup:231.50+/-84.50(cardiacfunctionclassⅡ216.50+/-96.00,classⅢ226.80+/-85.70,classⅣ244.00+/-73.00)vs.cardiacfunctionclassIgroup:217.50+/-89.00pg/mL,P>0.05].However,thelevelofsFaswassignificantlyhigherinthepatientswithCHFthanthoseofcardiacfunctionclassIgroup[CHFgroup:1353.30+/-507.71(cardiacfunctionclassⅡ1154.85+/-371.20,classⅢ1412.88+/-493.62,classⅣ1875.67+/-806.

简介：IthasbeenrevealedthatpolyⅠ:CisapotentstimulatorforNKcells,whichcaninduceNKcellrapidactivationandpreferentialaccumulationintoliver.However,theprocessmediatingtheinfluxofNKcellsremainsobscure.Inthisstudy,wefoundthatpolyⅠ:CadministrationincreasedtheportionandabsolutenumberofNKcellsinliver,butlargelydecreasedthoseinspleen.Therewerenoobviouschangesoftheselymphocytesinotherimmuneorgans.TheresultsfromsplenicadoptivetransferandsplenectomyshowedthattherecruitedspleenNKcellscontributedtotheaccumulationofNKcellsinliver,andthisprocesswasregulatedbytheproductionofchemokinesandthepresenceofTcells.Thisinvestigationwillhelptounderstandtheenhancedimmunecellrecruitmentinliveruponviralinfection.

简介：Mostoftheoculartumorshavepoorprognosis,andtheyremainadifficultproblemintheareaofophthalmology.Withtherapiddevelopmentofmolecularbiologyandimmunologictechniquesandthedeepresearchonoculartumorrelatedgenes,itbecomespossibletodiagnoseandtreatmalignanttumorsfromthemolecularlevel.Thetumornecrosisfactorrelatedapoptosis-inducingligand(TRAIL),amemberofthetumornecrosisfactor(TNF)superfamily,isapromisingcandidate,eitheraloneorincombinationwithestablishedcancertherapies,sinceitcaninitiateapoptosisthroughtheactivationoftheirdeathreceptors.TheabilityofTRAILtoselectivelyinduceapoptosisoftransformed,virus-infectedortumorcellsbutnotnormalcellspromotesthedevelopmentofTRAIL-basedcancertherapy.Here,wewillreviewTRAILanditsreceptors’structure,function,mechanismofactionandapplicationinoculartumorstherapy.

简介：Objective:Toinvestigatetheexpressionofmatrixmetalloproteinase-7(MMP-7)andFasligand(FasL)ingastriccancerandexploretheirroleinprogressionofgastriccancer.Methods:Formalin-fixedparaffinandembeddedtissuesofprimarygastriccancerandadjacentnon-tumormucosafrom113caseswereevaluatedforMMP-7,FasLandCapase-3expressionbystreptavidin-peroxidase(S-P)immunohistochemistry.Theexpressionofthefirsttwoproteinsincancercellsofprimaryfociwascomparedwithclinicopathologicalparametersoftumors.WealsoobservedthecorrelationofMMP-7andFasLexpressionwithCaspase-3expressionincancercellsofprimaryfoci.Results:MMP-7positiveimmunostainingwaslessfrequentlydetectedinadjacentepithelialcellsthanincancercellsofprimaryfociofgastriccancer(P<0.05,29.2%vs69.0%),andsowasFasL(P<0.05,34.5%vs54.0%).MMP-7expressionwasassociatedwithtumorsize,Borrmann'sclassification,invasivedepth,metastasisandTNMstaging(P<0.05),butnotwithgrowthpattern,Lauren'sclassification,orhistologicalclassification(P>0.05).FasLexpressionwascorrelatedwithtumorsize,invasivedepth,metastasis,Lauren'sclassification,histologicalclassification(P<0.05),whilenotwithBorrmann'sclassification,TNMstagingorgrowthpattern(P>0.05).CancercellsofprimaryfociexpressedlessCaspase-3thantheiradjacentepithelialcells(P<0.05,32.7%vs50.4%).TherewasanobviouscorrelationbetweenFasL,MMP-7andCaspase-3expressionincancercellsofprimaryfoci(P<0.05).Co-expressionofMMP-7andFasLparalleledwithCaspase-3expressionincancercellsofprimaryfoci(P<0.05).Conclusion:MMP-7andFasLexpressionwasup-regulatedingastriccarcinogenesisandwasprincipallyinvolvedinprogressionofgastriccancer.FasLexpressioncouldreflectthedifferentiationofgastriccancercellsandunderliethemolecularmechanismsofdifferentpathwaysofgastrictumorigenesis.Co-expressionofMMP-7andFasLcouldhaveapoptosis-inducingeffe

简介：无

简介：AbstractBackground:Perioperative neurocognitive disorders (PND) are a series of severe complications in the perioperative and anesthetic periods with a decline in memory, execution ability, and information processing speed as the primary clinical manifestation. This study aimed to evaluate the impact of edaravone (EDA) on PND and peripheral blood C-X-C motif chemokine ligand 13 (CXCL13) levels in elderly patients with hip replacement.Methods:A total of 160 elderly patients undergoing hip arthroplasty in Affiliated Dongguan People’s Hospital of Southern Medical University (from March 2016 to March 2018) were randomly and double-blindly categorized into an EDA group and a control group (CON). Group EDA was administered intravenously EDA 30 min before surgery, and group CON was administered intravenously saline. The cognitive function of the two groups was evaluated 1-day before the operation and at 1 and 12 months after surgery, and the incidence of post-operative delirium was tested on days 1, 3, and 7 after surgery using the Chinese version of the confusion assessment method. Serum CXCL13 and interleukin (IL)-6 concentrations were measured before anesthesia, during surgery (30 min after skin incision), and on days 1, 3, and 7 after surgery. The continuous variables in accordance with normal distribution were tested using the Student’s t test, the continuous variables without normal distribution using the Mann-Whitney U test, and categorical variables by the χ2 test or Fisher exact test.Results:The incidence of post-operative delirium within 7 days after surgery was significantly higher in group CON than that in group EDA (31.3% vs. 15.0%, t=-5.6, P < 0.001). The modified telephone interview for cognitive status and activities of daily life scores were significantly higher in the group EDA than those in the group CON at 1 month (39.63 ± 4.35 vs. 33.63 ± 5.81, t = -2.13, P < 0.05 and 74.3 ± 12.6 vs. 61.2 ± 13.1, t = -1.69, P < 0.05) and 12 months (40.13 ± 5.93 vs. 34.13 ± 5.36, t = -3.37, P < 0.05 and 79.6 ± 11.7 vs. 65.6 ± 16.6, t= -2.08, P < 0.05) after surgery; and the incidence of neurocognitive dysfunction was significantly lower in the group EDA than that in the group CON (P < 0.05). Serum CXCL13 and IL-6 concentrations were significantly lower in the group EDA than those in the group CON during and after surgery (P < 0.05).Conclusion:EDA can significantly reduce the serum concentrations of CXCL13 and IL-6 and improve the PND of patients.

简介：

简介：ObjectivesToinvestigatethechangeandclinicalsignificanceofclopidogrelonplateletmembraneCD40Lincoronaryarterydiseasepatientsbeforeandafterpercutaneouscoronaryintervention(PCI).Methods30caseswhowerediagnosiscoronaryarterydiseases(CAD)bycoronaryangiography,meanage56±9yearsold.Allthepatientswhohadnoantiplateletaggregationcontraindication,weretreatedwithstandardantianginapectorisdrugs.BeforePCI,allthepatientstookclopidogrel75mgperday.ActivatedplateletmembraneCD40LexpressratewasmeasuredbyflowcytometrybeforeandafterPCI6hours.ResultsActivatedplateletmembraneCD40Lexpressratewere3.73±2.15and2.46±0.90,respectivelyin30patientsbeforeandafterPCI6hours.ActivatedplateletmembraneCD40LexpressratewassignificantlydecreaseafterPCI6hoursthanthatbeforePCI(P<0.01).ConclusionsClopidogrelhassignificanceeffectonplateletmembraneCD40LincoronaryarterydiseasepatientsundergoingPCI.Clopidogrelcansuppressionplateletactivationandpreventthromboembolismeventoccurrence.

简介：AbstractHistorically, breast cancer has been regarded as an immunogenic "cold" tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer. This review discusses the immune system, immune features of breast cancer, and the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors used in the treatment of breast cancer. High T lymphocyte infiltration and mutation burden were observed in triple-negative breast cancer and human epidermal growth factor receptor 2 positive breast cancer. Increasing breast cancer immunogenicity and modulating the tumor microenvironment has been reported to improve the therapeutic efficacy of immunotherapy. Recent clinical trials involving PD-1/PD-L1 inhibitors monotherapy in breast cancer has revealed little efficacy, which highlights the need to develop combinations of PD-1/PD-L1 inhibitors with chemotherapy, molecularly targeted therapies, and other immunotherapies to maximize the clinical efficacy. Collectively, the immunotherapy might be a promising therapeutic strategy for breast cancer and several clinical trials are still on-going.

简介：无

简介：AbstractBackground:PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods:Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results:Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions:Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.

简介：摘要目的探讨CC趋化因子ligand-5(CCL5)促进在肝脏缺血再灌注损伤早期巨噬细胞浸润的机制。方法使用成年雄性C57BL/6野生型和CCL5缺陷小鼠进行实验，随机分为4组：假手术组(假手术组小鼠经历缺血灌注模型方案，但没有进行血管闭塞，n＝10)；缺血再灌注模型组(用异氟烷麻醉小鼠，进行中线剖腹手术，并将一个无创伤夹子放置在静脉门、肝动脉和胆管上，以中断左侧外侧叶和中叶的血液供应，在部分肝脏缺血60 min后，移除夹子以开始再灌注，n＝10)；CCL5拮抗剂＋模型组[在即将开始再灌注之前，CCL5拮抗剂＋模型组接受单次推注静脉注射趋化因子受体5(CCR5)受体拮抗剂马拉维诺，n＝10]；CCL5缺陷组(CCL5缺陷小鼠，n＝10)；通过收集小鼠血液用VTROS DT60 Ⅱ化学系统检测谷丙转氨酶(ALT)含量及髓过氧化物酶(MPO)活性；通过实时定量反转录聚合酶链反应(RT-qPCR)检测ALT mRNA及MPO mRNA的表达；通过流式细胞术检测巨噬细胞的数量；通过组织学和免疫组织化学检测巨噬细胞对肺部的浸润情况；通过蛋白质免疫印迹检相关炎性因子的蛋白表达。通过单因素方差分析组间的统计学差异。结果与假手术组比较缺血再灌注模型组中ALT含量[(521.36±20.65)比( 4126.55±326.68)，F＝16.237，P<0.05]及MPO[(1.78±0.54)比(7.66±2.34)，F＝14.211，P<0.05]活性升高，CCL5拮抗剂＋模型组较缺血再灌注模型组降低(P<0.05)，差异有统计学意义。在前1～3 h缺血再灌注模型组与CCL5缺陷组中CD45 ＋数量比较差异无统计学意义(P>0.05)，在第24小时缺血再灌注模型组较CCL5缺陷组CD45＋的数量升高[(2.91±0.23)比(1.65±0.17)，F＝16.311，P<0.05]。再灌注后1、2、8和24h中，发现缺血再灌注模型组CD68 ＋细胞数量较假手术组高[(94.62±8.55)比(23.68±3.11)，F＝16.352，P<0.05]，差异有统计学意义，而在缺血再灌注早期CCL5缺陷组中较缺血再灌注模型组降低[(76.38±6.77)比(94.62±8.55)，F＝16.352，P<0.05]，差异有统计学意义。与与假手术组比较，缺血再灌注模型肿瘤坏死因子(TNF)-α[(1.12±0.23)比(3.24±0.42)，F＝11.352，P<0.05] 、白细胞介素(IL)-1β[(1.03±0.08)比(2.87±0.35)，F＝12.452，P<0.05] 、IL-6[(0.95±0.02)比(2.58±0.21)，F＝15.652，P<0.05]的蛋白表达升高，差异有统计学意义。而CCL5拮抗剂＋模型组较缺血再灌注模型组TNF-α[(3.24±0.42)比(1.35±0.14)，F＝14.252，P<0.05]、IL-1β[(2.87±0.35)比(1.22±0.15)，F＝13.723，P<0.05]、IL-6[(2.58±0.21)比(1.35±0.26)，F＝14.312，P<0.05]的蛋白表达降低，差异有统计学意义。结论CCL5促进早期肝脏缺血再灌注期间循环巨噬细胞对肝脏的浸润，并介导随后的促炎症损伤。

简介：Blockadeofimmunecheckpointshasrecentlyemergedasanoveltherapeuticstrategyinvarioustumors.Inparticular,monoclonalantibodiestargetingprogrammedcelldeath1(PD-1)oritsligand(PD-L1)havebeenmoststudiedinlungcancer,andPD-1inhibitorsarenowestablishedagentsinthemanagementofnon-smallcelllungcancer(NSCLC).ThereportsonhighprofileclinicaltrialshaveshowntheassociationofPD-L1expressionbyimmunohistochemistry(IHC)withhigheroverallresponseratestothePD-1/PD-L1axisblockadesuggestingthatPD-L1expressionmayserveasapredictivemarker.Unfortunately,however,eachPD-1orPD-L1inhibitoriscoupledwithaspecificPD-L1antibody,IHCprotocolandscoringsystemforthebiomarkerassessment,makingthehead-to-headcomparisonofthestudiesdifficult.Similarly,multipleclinicalseriesthatcorrelatedPD-L1expressionwithclinicopathologicand/ormolecularvariablesand/orsurvivalhavereportedconflictingresults.Thediscrepancycouldbeexplainedbythedifferencesinethnicityand/orhistologictypesincludedinthestudies,butitappearstobeattributedinparttothedifferencesinPD-L1IHCmethods.Thus,orchestratedeffortstostandardizethePD-L1IHCarewarrantedtoestablishtheIHCasapredictiveand/orprognosticbiomarkerinNSCLC.

简介：AbstractBackground:We previously found that the intestinal epithelial chemokine (C-C motif) ligand 7 (CCL7) plays an important role in the development of toxin-induced acute liver damage. The detailed effects of intestinal epithelial CCL7 on chronic diseases; however, are still unclear. Here, we aimed to investigate the impact of intestinal epithelial CCL7 overexpression on high-fat diet (HFD)-induced obesity and steatohepatitis in mice.Methods:Intestinal epithelial CCL7 overexpression (CCL7tgIEC) mice and their wild-type (WT) littermates were fed with normal chow or HFD for 16 weeks to induce obesity and non-alcoholic fatty liver disease. Body weight gain, as well as adipose tissue index were assessed. Liver injury was monitored by histological analysis and real time polymerase chain reaction. Gut microbial composition was analyzed by 16S rRNA gene sequencing.Results:We found that the CCL7tgIEC mice on a HFD had markedly decreased weight gain (8.9 vs. 17.0 g, P < 0.05) and a lower adipose tissue index that include mesenteric fat (1.0% vs. 1.76%, P < 0.05), gonadal fat (2.1% vs. 6.1%, P < 0.05), subcutaneous fat (1.0% vs. 2.8%, P < 0.05) compared to WT animals. HFD-induced glucose intolerance and insulin resistance were also significantly improved in CCL7tgIEC mice compared to WT. Furthermore, HFD-fed CCL7tgIEC mice displayed less hepatic lipid accumulation and lower expression of inflammatory factors than WT mice. 16S rRNA gene sequencing demonstrated that CCL7 overexpression in intestinal epithelial cells improved HFD-induced gut microbial dysbiosis.Conclusions:Our study revealed that CCL7 overexpression in the intestinal epithelium protects mice against the progression of diet-induced obesity, hepatic steatosis, and enteric dysbiosis.

简介：AbstractIn recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.